Garofalo Health Care S.p.A (GHC) Fair Value & Analysis
Healthcare · IT · Market cap €473M
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 5 days ago
Price vs Fair Value (12 months)
12‑month range €4.21 – €5.59 · fair‑value band €3.04 – €7.29 · the €5.16 price screens above the €5.03 fair value. As of Jun 24, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Garofalo Health Care S.p.A (GHC) currently trades at €5.16, while our model-based Fair Value estimate is €5.03 — implying the stock looks roughly 2.5% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Garofalo Health Care S.p.A generated revenue of €489M at a net margin of 4.4%. Revenue grew 3.2% year over year. It earns a return on equity of 6.2%. Net debt stands at €182M. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
Garofalo Health Care S.p.A., together with its subsidiaries, operates healthcare clinics in Italy. It operates through Hospital and Social/Dependency Care segments. The company offers high-complexity surgery, medium- and low-complexity surgery, emergency surgery, medicine, clinical and interventional cardiology, and extended and intensive care units, as well as motor, neurological, cardiac, and nutritional rehabilitation. It also operates centers for patients in coma and persistent vegetative states; and psychiatric and diagnostic centers. The company was founded in 2000 and is based in Rome, Italy. Garofalo Health Care S.p.A. is a subsidiary of Larama 98 S.p.A.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Garofalo Health Care S.p.A reported revenue of €479M in FY2025 versus €278M in FY2021, a compound +14.6%/yr. Reported net income was €23.4M in FY2025, compounding +5.6%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc H1CA34 | R$95.75 | R$123.65 | +29% |
| Fresenius SE FSNUY | $11.30 | $8.61 | -24% |
| 5225 5225 | 8.67 MYR | 3.08 MYR | -64% |
| IHHHF IHHHF | $1.71 | $0.7400 | -57% |
| Tenet Healthcare Corporation THC | $164.77 | $280.85 | +70% |
| Rede D'Or São Luiz S.A RDOR3 | R$32.50 | R$46.04 | +42% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Garofalo Health Care S.p.A (GHC) undervalued?
What is the fair value of GHC?
What is the quality score of GHC?
What is the revenue of Garofalo Health Care S.p.A (GHC)?
What is the net profit margin of GHC?
Does Garofalo Health Care S.p.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.